Login to Your Account

Financings Roundup

Affinium MRSA Candidate Draws $15M Financing

By Catherine Shaffer

Tuesday, August 30, 2011
All three of Affinium Pharmaceuticals Inc.'s original Series A investors have returned for a $15 million follow-on financing. SV Life Sciences, Genesis Capital Partners and Forward Ventures are joined by new investor Ontario Emerging Technologies Fund in a financing round that will support completion of a Phase II trial of Affinium's oral antibiotic AFN-1252, and Phase I trials of an I.V. formulation of the same drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription